Boston Scientific Corporation (BSX) Earnings Call Transcripts

Boston Scientific Corporation's Latest Earnings Call - September 10, 2026

In the Q3 2026 earnings call for Boston Scientific Corporation, management indicated that the company is unlikely to meet its previously set guidance for the quarter and the full year due to an 8-day cyberattack that disrupted operations. The CEO, Mike Mahoney, emphasized that while operations are now fully restored, the financial impact and recapture rate from lost procedures remain uncertain. The company is targeting organic growth of 2% to 4% for 2027, but this is contingent on market recovery and product launches, particularly in the WATCHMAN and electrophysiology (EP) segments.

Reported metrics

Guidance from management

Management has indicated that they will not provide official guidance for 2027 until the October earnings call, but they aim for organic growth of 2% to 4% in 2027 based on recovery from the cyberattack and product launches.

What management said

I think the big thing is the whole theme of the business, which will -- we can talk about are unchanged based on the cyberattack. But we just have to get a better handle on your question on the recapture rate and the financial impact. And we'll know a lot more in the next 45 days. So we'll be able to give a better sense. We won't give our official guide in October, we'll probably provide a better framework for '27 a...

So I would say in a positive note, maybe it doesn't help -- the industry does help each other out of this one. There's a lot of competitors that we compete with, but we're all kind of under the same cyber risk despite all of our great efforts and investments. And so a lot of companies share best practice to share information. So it's a nice thing to say. So we're very thankful for that.

What analysts pressed on

Analysts expressed concerns regarding the impact of the cyberattack on future earnings and the ability to recapture lost market share, particularly in the WATCHMAN segment. There were also questions about the competitive landscape in electrophysiology and the potential for pricing pressure in the market.

Main topics on the call

• Cyberattack Impact — Management reported an 8-day disruption due to a cyberattack, affecting shipping and manufacturing. CEO Mike Mahoney stated, "we just have to sift through what the recapture rate is and that's still what we're working th...
• WATCHMAN Market Outlook — The WATCHMAN product is expected to see a mid- to high single-digit year-over-year decline in the second half of 2026, with similar expectations for 2027. Mahoney noted, "we don’t want to call the market improving until ...
• Electrophysiology Growth — Management remains optimistic about the electrophysiology market, expecting continued growth despite competitive pressures. Mahoney stated, "We believe so" when asked if the market would grow in double digits.
• Product Launches and Pipeline — Boston Scientific is focusing on upcoming product launches, including the FARAWAVE Ultra and ICE platforms, expected in the second half of 2027. Mahoney highlighted, "we have a cadence of products that are coming."

Read the full Boston Scientific Corporation transcript (September 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 84 Boston Scientific Corporation earnings call transcripts on record, spanning January 14, 2020 to September 10, 2026. Based on this history, Boston Scientific Corporation reports quarterly. The most recent call on file is dated September 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BSX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

84

First call

January 14, 2020

Most recent

September 10, 2026

Reporting cadence

quarterly